{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Thymosin Beta-4 (full length)",
    "short_name": "Thymosin Beta-4 (full length)",
    "aliases": [],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "status": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-20",
      "human_use_note": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "evidence_refs": []
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "tendon and ligament recovery support",
        "soft tissue healing after overuse or injury",
        "return-to-training support during rehab",
        "joint comfort and mobility support",
        "interest in tissue repair pathways"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-20",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Thymosin Beta-4 (full length)",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_injury_healing",
        "topic_muscle_recovery"
      ]
    },
    "slug": "thymosin-beta-4-full",
    "practical": {
      "schema_version": "practical_block_v1",
      "bottom_line": "Thymosin beta-4 full-length is the canonical TB4 peptide discussed in wound and tissue repair research. In consumer markets, it is frequently confused with fragments and look-alike products, which creates identity and quality risk. The practical takeaway is that sourcing, labeling accuracy, and medical appropriateness drive most of the real-world downside.",
      "benefits": [
        "Soft-tissue recovery interest after overuse or injury",
        "Skin and wound recovery interest in research contexts",
        "Return-to-training support interest during rehabilitation periods",
        "Preference for full-length identity clarity in product discussions"
      ],
      "side_effects_common": [
        "Injection-site irritation or discomfort",
        "Headache",
        "Nausea",
        "Fatigue"
      ],
      "side_effects_serious": [
        "Allergic reaction with hives, facial swelling, or trouble breathing",
        "Chest pain, fainting, or severe shortness of breath",
        "Severe swelling, rapidly spreading redness, or drainage at an injection site"
      ],
      "who_should_be_cautious": [
        "Active cancer or recent cancer treatment",
        "People using anticoagulants or antiplatelets",
        "Bleeding disorders",
        "Pregnancy or breastfeeding",
        "Children and adolescents"
      ]
    }
  },
  "interactions": {
    "drug_classes": [
      "anticoagulants-antiplatelets"
    ],
    "supplement_classes": [
      "anticoagulant-herbs"
    ],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "bottom_line": "Thymosin beta-4 full-length is the canonical TB4 peptide discussed in wound and tissue repair research. In consumer markets, it is frequently confused with fragments and look-alike products, which creates identity and quality risk. The practical takeaway is that sourcing, labeling accuracy, and medical appropriateness drive most of the real-world downside.",
    "benefits": [
      "Soft-tissue recovery interest after overuse or injury",
      "Skin and wound recovery interest in research contexts",
      "Return-to-training support interest during rehabilitation periods",
      "Preference for full-length identity clarity in product discussions"
    ],
    "side_effects_common": [
      "Injection-site irritation or discomfort",
      "Headache",
      "Nausea",
      "Fatigue"
    ],
    "side_effects_serious": [
      "Allergic reaction with hives, facial swelling, or trouble breathing",
      "Chest pain, fainting, or severe shortness of breath",
      "Severe swelling, rapidly spreading redness, or drainage at an injection site"
    ],
    "who_should_be_cautious": [
      "Active cancer or recent cancer treatment",
      "People using anticoagulants or antiplatelets",
      "Bleeding disorders",
      "Pregnancy or breastfeeding",
      "Children and adolescents"
    ]
  }
}
